AI-Powered MRI could spot cancer early in kids with NF1

NCT ID NCT04763109

Recruiting now Knowledge-focused Sponsor: Nicole Baca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing whether a whole-body MRI scan, analyzed by artificial intelligence, can reliably detect pre-cancerous changes in children with neurofibromatosis type 1 (NF1). Fifteen children will receive three MRI scans over a year. The goal is to see if the scans are consistent and if the AI can spot changes that might indicate early cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Whole-body Magnetic Resonance Imaging with Artificial Intelligence analysis
What this could lead to: If successful, this could lead to a new, non-invasive way to spot early cancer signs in children with NF1, allowing for earlier treatment.
What could go wrong: This is a very small pilot study (15 people) focused on feasibility, not on proving the method works. The AI algorithm may not be accurate enough, and results may not apply to all NF1 patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS TYPE 1

Contacts and locations

Locations

Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.